|Bid||7.69 x 800|
|Ask||7.72 x 1800|
|Day's Range||7.51 - 7.74|
|52 Week Range||2.37 - 9.93|
|Beta (5Y Monthly)||2.98|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
By John Vandermosten, CFA NYSE:CVM READ THE FULL CVM RESEARCH REPORT The Last Review? CEL-SCI Corporation (NYSE:CVM) today announced its second Independent Data Monitoring Committee (IDMC) review this year for the IT MATTERS Phase III Multikine study for head and neck cancer. We believe that the longer than expected duration of the trial combined with the IDMC recommendation to continue its
By John Vandermosten, CFA NYSE:CVM While CEL-SCI (NYSE:CVM) has experienced outstanding performance over the last several quarters due to the anticipated readout of Multikine in the IT-MATTERS clinical trial, the company also has a platform technology in development that has impressive potential in treating a number of human diseases. This platform is known as the Ligand
In late May 2019, Zacks was treated to an onsite tour of CEL-SCI’s (CVM) 73,000 square foot manufacturing facility in Elkridge, Maryland. As we drove to the industrial park southwest of Baltimore, we came upon CEL-SCI’s facility, nestled among warehouses and light manufacturing enterprises. With multiple delivery bays and administrative offices up front, we entered to meet with Chief Scientific Officer Dr. Eyal Talor who introduced us to the staff and provided background on the facility in preparation for our walk through.
OncoCyte Corporation (NYSE: OCX ) is set to join the Russell 2000, Russell 3000 and Russell Microcap Indexes July 1. The Russell 3000 Index is a capitalization-weighted stock market index maintained by ...
By John Vandermosten, CFA NYSE:CVM READ THE FULL CVM RESEARCH REPORT CEL-SCI Corporation (NYSE:CVM) reported fiscal second quarter 2019 results for the three month period ending March 31, 2019. A the end ...
The Vienna, Virginia-based company said it had a loss of 22 cents per share. Losses, adjusted for non-recurring costs, were 19 cents per share. The cancer immunotherapy company posted revenue of $150,800 ...
This assessment is based on historical event rates which suggests the final event will take place in the next few months. In CEL-SCI Corporation’s (CVM) a recent update to clinicaltrials.gov, we noticed that the anticipated completion was changed from December 2017 to December 2020. Management stated that the new anticipated completion date should read September 2019.
On a per-share basis, the Vienna, Virginia-based company said it had profit of 2 cents. Losses, adjusted for non-recurring gains, were 17 cents per share. The cancer immunotherapy company posted revenue ...
We are initiating coverage of CEL-SCI Corporation (CVM) with a $14.00 price target based on our estimates for a 2021 US and 2022 EU launch of lead compound Multikine in squamous cell carcinoma of the head and neck (SCCHN). The clinical-stage company is developing this biological product which contains multiple cytokines to enable the body to mount an anti-tumor immune response. The biologic is being developed as a first line therapy that will be administered to newly diagnosed, but not yet treated, head and neck cancer patients prior to their receiving standard of care (SOC), which includes surgery, chemotherapy and radiotherapy.